非小细胞肺癌患者EML4-ALK融合基因突变对个体化靶向治疗预后的影响

doi:10.3969/j.issn.1671-7171.2021.10.012

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1264 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the mutation of echinoderms microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene in patients with non-small cell lung cancer (NSCLC) and explore its impact on the prognosis of individualized targeted therapy. 【Methods】A total of 110 NSCLC tissue specimens preserved in our hospital from February 2016 to February 2018 were selected. The mutation of EML4-ALK fusion gene was detected by real-time fluorescence quantitative PCR. The effect of the mutation on individualized targeted therapy were analyzed. 【Results】The mutation of EML4-ALK fusion gene was detected in 13 cases, the mutation rate was 11.82% (13/110). Of which, the mutation rates of EML4-ALK fusion gene were 19.23% and 23.81% in patients aged < 60 years and TNM stage Ⅲ,respectively, which were significantly higher than those in patients aged ≥ 60 years and stage Ⅰ-Ⅱ(P<0.05); The median survival time of EML4-ALK fusion gene mutation and non-mutation patients was 14.00 months (95%CI:11.71-16.29) and 13.00 months (95%CI:12.39-13.61), there was no significant difference (P> 0.05). 【Conclusion】The mutation of EML4-ALK fusion gene in NSCLC patients is related to patient's age and TNM stage, while it has no significant effect on the prognosis of individualized targeted therapy.

Key words： Carcinoma, Non-Small-Cell Lung Antineoplastic Agents Genes Prognosis

Received: 20 July 2020

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	BAI Xue-mei
	GUO Xuan
	ZHAO Xin-han
	et al

Cite this article:

BAI Xue-mei,GUO Xuan,ZHAO Xin-han, et al. Mutation and Significance of EML4-ALK Fusion Gene in NSCLC Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(10): 1483-1485.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.10.012 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I10/1483

[1] 徐利芬,陈佳,龙昭玲,宋翼.非小细胞肺癌患者表皮生长因子受体和棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶与病理特征的相关性[J].中华老年医学杂志,2016,35(11):1192-1195.
[2] 徐爱茹,马为.ALK融合基因阳性的晚期非小细胞肺癌靶向治疗进展[J].现代肿瘤医学,2019,27(3):529-533.
[3] 唐艳萍,谭晓玉,蔡政民,等.非小细胞肺癌表皮生长因子受体基因突变和 EM L4-ALK 融合基因表达的研究[J].检验医学与临床,2016,13(24):3458-3460.
[4] 俞晓燕.非小细胞肺癌胸水样本不同预处理方式对EML4_ALK融合基因RT-PCR法检测的影响[J].医药前沿,2017,7(24):369-371.
[5] ANDREIA TERESO,LUíS CARRETO,MANUELA BAPTISTA,et al.Interstitial lung disease induced by crizotinib in non-small-cell lung cancer.[J].Acta Med Port,2019,32(3):236-239.
[6] ZHANG ML,WANG Q,DING Y,et al.CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer[J].Thoraci Oncol,2018,13(11):1792-1797.
[7] CAMIDGE D R, KIM H R, AHN M J, et al. Brigatinib versus crizotinib in alk-positive non-small-cell lung cancer[J].N Engl J Med,2018;379(21):2027-2039.
[8] TAN S, SUN D, PU W, et al. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer[J].Mol Cancer, 2018,17(1):138-140.
[9] XU C W, WANG W X, CHEN Y P, et al. Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib[J].J Transl Med,2018,16(1):93-96.
[10] XU Y, ZHANG F, PAN X, et al. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance[J].Cancer Commun (Lond),2018,38(1):19-22.
[11] MELLAS N,HIJRI F,BENBRAHIM Z,et al.Crizotinib in non-small cell lung cancer[J].J Thoracic Oncology,2018,13(11):1792-1797.
[12] DAVID M STRAUGHAN,SAID C AZOURY,VIVEK SHUKLA.Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer[J].Current drug targets,2016,17(6):739-745.
[13] CAMIDGE D R, KIM H R, AHN M J, et al. Brigatinib versus crizotinib in advanced alk inhibitor-naive alk-positive non-small cell lung cancer: second interim analysis of the phase Ⅲ Alta-1L trial[J].J Clin Oncol,2020,38(31):3592-3603.